Abstract:Our study indicated that the 14‐gene‐related prognostic signature gene could serve as a novel biomarker for predicting breast cancer patients' prognosis. We found that immunotherapy might play a vital role in therapeutic schedule based on the level and difference of immune‐related cells and pathways in different risk groups. Background Breast cancer (BC), a malignant tumor, is a significant cause of death and disability among women globally. Recent research indicates that copy number variation plays a crucial role in tumor development. In this study, we employed the Single‐Cell Variational Aneuploidy Analysis (SCEVAN) algorithm to differentiate between malignant and non‐malignant cells, aiming to identify genetic signatures with prognostic relevance for predicting patient survival. Methods We analyzed gene expression profiles and associated clinical data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Using the SCEVAN algorithm, we distinguished malignant from non‐malignant cells and investigated cellular interactions within the tumor microenvironment (TME). We categorized TCGA samples based on differentially expressed genes (DEGs) between these cell types. Subsequent Kyoto Encyclopedia of Genes and Genomes pathway analysis was conducted. Additionally, we developed polygenic models for the DEGs using least absolute shrinkage and selection operator‐penalized Cox regression analysis. To assess the prognostic accuracy of these characteristics, we generated Kaplan–Meier and receiver operating characteristic curves from training and validation datasets. We also monitored the expression variations of prognostic genes across the pseudotime of malignant cells. Patients were divided into high‐risk and low‐risk groups based on median risk scores to compare their TME and identify potential therapeutic agents. Lastly, polymerase chain reaction was used to validate seven pivotal genes. Results The SCEVAN algorithm identified distinct malignant and non‐malignant cells in GSE180286. Cellchat analysis revealed significantly increased cellular communication, particularly between fibroblasts, endothelial cells and malignant cells. The DEGs were predominantly involved in immune‐related pathways. TCGA samples were classified into clusters A and B based on these genes. Cluster A, enriched in immune pathways, was associated with poorer prognosis, whereas cluster B, predominantly involved in circadian rhythm pathways, showed better outcomes. We constructed a 14‐gene prognostic signature, validated in a 1:1 internal TCGA cohort and external GEO datasets (GSE42568 and GSE146558). Kaplan–Meier analysis confirmed the prognostic signature's accuracy (p

A 41-Gene Signature Derived from Breast Cancer Stem Cells As a Predictor of Survival

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer.

A Prognostic Signature Associated with Cell Senescence Predicts Survival Outcomes and Strongly Associates with Immunotherapy and Chemotherapy Response in Breast Cancer

Development of a novel prognostic signature based on single‐cell combined bulk RNA analysis in breast cancer

Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (-) Breast Cancer

Identification of a 4-Mrna Metastasis-Related Prognostic Signature for Patients with Breast Cancer.

Identification of a 9-Gene Prognostic Signature for Breast Cancer.

Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients

Cancer Stem Cell Associated Eight Gene-Based Signature Predicts Clinical Outcomes of Colorectal Cancer

An Immune‐related Prognostic Signature for Predicting Breast Cancer Recurrence

Gene Expression Biomarkers to Predict Overall Survival of Prostate Cancer Patients

414P Identification of a Stemness-Related Gene Signature for Predicting Prognosis of Patients with Adjuvant Chemotherapy in Colorectal Cancer

A Novel Signature Based on Cancer-Associated Fibroblast Genes to Predict Prognosis, Immune Feature, and Therapeutic Response in Breast Cancer.

Development of an Immune-Related Prognostic Signature in Breast Cancer

Prognostic Value of a BCSC-associated Microrna Signature in Hormone Receptor-Positive HER2-negative Breast Cancer.

A Prognostic 4-Gene Expression Signature for Patients with HER2-negative Breast Cancer Receiving Taxane and Anthracycline-Based Chemotherapy

Integrative analysis reveals a four-gene signature for predicting survival and immunotherapy response in colon cancer patients using bulk and single-cell RNA-seq data